ãã€ãªãã¯ãããžãŒäŒæ¥ã§ãã Phio Pharmaceuticals Corp. ã¯ãç±³åœã§å
ç«è
«çæ²»çè¬ãéçºããŠããŸããå瀟ã¯ãè
«çèªçºæ§ã®å
ç«ã·ã¹ãã ã®æå¶ããµã€ã¬ã³ã·ã³ã°ããããšã«çŠç¹ãåœãŠã INTASYL æ²»çãã©ãããã©ãŒã ãæäŸããŠããŸããå瀟ã¯ãé€å现èç§»æ€ (ACT) ã§äœ¿çšããããã«å
ç«çްèäžã®ãã§ãã¯ãã€ã³ãã¿ã³ãã¯è³ª PD-1 ãæšçãšãã PH-762ãACT ã§äœ¿çšããããã« T 现èãšããã¥ã©ã«ãã©ãŒçްèã«ååšãããã§ãã¯ãã€ã³ãã¿ã³ãã¯è³ªã§ããæå¶å
ç«åå®¹äœ TIGIT ãæšçãšãã PH-804ãããã³å
ç«çްèãäœå
ã®ç¡å®³ãªçްèãæ»æããã®ãé²ã PD-L1 ã¿ã³ãã¯è³ªãæšçãšãã PH-790 ãéçºããŠããŸããå瀟㯠Gustave Roussy ããã³ Medigene AGããªãã³ã« Helmholtz Zentrum MÃŒnchen ãšææºããŠããŸããPhio Pharmaceuticals ã¯ãæ°ãã T 现èããŒã¹ã®çå
ç«çæ³ã®èšåºéçºã§ AgonOx Inc. ãšææºããŠããŸããå瀟ã¯ä»¥åã¯RXi Pharmaceuticals CorporationãšããŠç¥ãããŠããã2018幎11æã«Phio Pharmaceuticals Corp.ã«ç€Ÿåã倿ŽããŸãããPhio Pharmaceuticals Corp.ã¯2011幎ã«èšç«ãããããµãã¥ãŒã»ããå·ããŒã«ããã«æ¬ç€Ÿã眮ããŠããŸãã